Monitoring and Improving Antipsychotic Adherence in Outpatient Forensic Diversion Programs

Chapter 19 - Monitoring and Improving Antipsychotic Adherence in Outpatient Forensic Diversion Programs

from Part III - Psychopharmacological Treatment Considerations

Published online by Cambridge University Press: 19 October 2021

Jonathan M. Meyer

Edited by

Katherine Warburton and

Stephen M. Stahl

Show author details

Katherine Warburton: Affiliation:
University of California, Davis
Stephen M. Stahl: Affiliation:
University of California, San Diego

Book contents

Get access

Summary

California has the largest population of mentally ill defendants nationwide, and on June 27, 2018, the governor signed into law Assembly Bill 1810 that offered every county the opportunity to establish diversion program procedures (Section 15), and opened program access to all mental health diagnoses excluding antisocial personality disorder, borderline personality disorder, and pedophilia. This measure thus reflects the increasing nationwide interest in channeling seriously mentally ill individuals away from traditional legal processes into pre-trial diversion programs. On an individual level the goal is to provide treatment for mental health conditions, decrease the legal burden and consequences of arrest, and facilitate integration with community support structures.

Type: Chapter
Information: Decriminalizing Mental Illness , pp. 200 - 209

DOI: https://doi.org/10.1017/9781108920698 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Subscription

Individual access

Subscriptions are only available for individuals and not institutional access. Subscribe now

References

California Assembly Bill 1810. Pretrial Diversion, Section 15. 2018.Google Scholar

Case, B, Steadman, HJ, Dupuis, SA, et al. Who succeeds in jail diversion programs for persons with mental illness?: a multi-site study. Behav Sci Law. 2009; 27(5): 661–674.Google Scholar

Renner, M, Newark, C, Bartos, BJ, et al. Length of stay for 25, 791 California patients found incompetent to stand trial. J Forensic Leg Med. 2017; 51: 22–26.Google Scholar

Steadman, HJ, Redlich, A, Callahan, L, et al. Effect of mental health courts on arrests and jail days: a multisite study. Arch Gen Psychiatry. 2011; 68(2): 167–172.Google Scholar

Gill, KJ, Murphy, AA. Jail diversion for persons with serious mental illness coordinated by a prosecutor’s office. Biomed Res Int. 2017; 2017: 7917616.Google Scholar

Comartin, E, Kubiak, SP, Ray, B, et al. Short- and long-term outcomes of mental health court participants by psychiatric diagnosis. Psychiatr Serv. 2015; 66(9): 923–929.Google Scholar

Oueslati, B, Fekih-Romdhane, F, Mrabet, A, et al. Correlates of offense recidivism in patients with schizophrenia. Int J Law Psychiatry. 2018; 58: 178–183.Google Scholar

Rezansoff, SN, Moniruzzaman, A, Fazel, S, et al. Adherence to antipsychotic medication and criminal recidivism in a Canadian provincial offender population. Schizophr Bull. 2017; 43(5): 1002–1010.Google Scholar

Lamberti, JS. Understanding and preventing criminal recidivism among adults with psychotic disorders. Psychiatr Serv. 2007; 58(6): 773–781.Google Scholar

Dufort, A, Zipursky, RB. Understanding and managing treatment adherence in schizophrenia. Clin Schizophr Relat Psychoses. 2019. Jan 3. doi:10.3371/CSRP.ADRZ.121218. [Epub ahead of print]Google Scholar

Brain, C, Sameby, B, Allerby, K, et al. Twelve months of electronic monitoring (MEMS) in the Swedish COAST-study: a comparison of methods for the measurement of adherence in schizophrenia. Eur Neuropsychopharmacol. 2014; 24(2): 215–222.Google Scholar

Remington, G, Teo, C, Mann, S, et al. Examining levels of antipsychotic adherence to better understand nonadherence. J Clin Psychopharmacol. 2013; 33(2): 261–263.Google Scholar

Byerly, MJ, Thompson, A, Carmody, T, et al. Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. Psychiatr Serv. 2007; 58(6): 844–847.Google Scholar

Velligan, DI, Wang, M, Diamond, P, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv. 2007; 58(9): 1187–1192.Google Scholar

McCutcheon, R, Beck, K, Bloomfield, MA, et al. Treatment-resistant or resistant to treatment?: antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. J Psychopharmacol. 2015; 29(8): 892–897.Google Scholar

Meyer, JM. Converting oral to long acting injectable antipsychotics: a guide for the perplexed. CNS Spectr. 2017; 22(S1): 14–28.Google Scholar

Velligan, DI, Lam, YW, Glahn, DC, et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull. 2006; 32(4): 724–742.Google Scholar

Xu, DR, Gong, W, Gloyd, S, et al. Measuring adherence to antipsychotic medications for schizophrenia: concordance and validity among a community sample in rural China. Schizophr Res. 2018; 201: 307–314.Google Scholar

Alphs, L, Mao, L, Rodriguez, SC, et al. Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia. J Clin Psychiatry. 2014; 75(12): 1388–1393.Google Scholar

Alphs, L, Benson, C, Cheshire-Kinney, K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015; 76(5): 554–561.Google Scholar

Kishimoto, T, Hagi, K, Nitta, M, et al. Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies. Schizophr Bull. 2018; 44(3): 603–619.Google Scholar

Alkermes Inc. Aristada Initio Package Insert. Walltham MA: Alkermes Inc.; 2018.Google Scholar

Indivior Inc. Perseris Package Insert. North Chesterfield, VA: Indivior Inc.; 2018.Google Scholar

Hard, ML, Mills, RJ, Sadler, BM, et al. Aripiprazole lauroxil: pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia. J Clin Psychopharmacol. 2017; 37(3): 289–295.Google Scholar

Hard, ML, Mills, RJ, Sadler, BM, et al. Pharmacokinetic profile of a 2-month dose regimen of aripiprazole lauroxil: a phase I study and a population pharmacokinetic model. CNS Drugs. 2017; 31(7): 617–624.Google Scholar

Meyer, JM. Understanding depot antipsychotics: an illustrated guide to kinetics. CNS Spectr. 2013; (18 Suppl 1): 55–68.Google Scholar

Leucht, S, Cipriani, A, Spineli, L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382(9896): 951–962.Google Scholar

Meyer, JM, Rosenblatt, LC, Kim, E, et al. The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia. J Clin Psychiatry. 2009; 70(3): 318–325.Google Scholar

McCutcheon, R, Beck, K, D’Ambrosio, E, et al. Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr Scand. 2017; 137(1): 39–46.Google Scholar

Meyer, JM, Stahl, SM. The Clozapine Handbook. Cambridge, UK: Cambridge University Press; 2019.Google Scholar

Meyer, JM. A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes. CNS Spectr. 2014; 19(5): 432–438.Google Scholar

Iyo, M, Tadokoro, S, Kanahara, N, et al. Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J Clin Psychopharmacol. 2013; 33(3): 398–404.Google Scholar

Sparshatt, A, Taylor, D, Patel, MX, et al. A systematic review of aripiprazole – dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry. 2010; 71(11): 1447–1556.CrossRef Google Scholar PubMed

Rostami-Hodjegan, A, Amin, AM, Spencer, EP, et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol. 2004; 24(1): 70–78.CrossRef Google Scholar PubMed

Wei, FC, Jann, MW, Lin, HN, et al. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy. J Clin Psychiatry. 1996; 57(7): 298–302.Google Scholar

Ereshefsky, L, Jann, MW, Saklad, SR, et al. Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiatry. 1985; 20(3): 329–332.Google Scholar

Bishara, D, Olofinjana, O, Sparshatt, A, et al. Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response. J Clin Psychopharmacol. 2013; 33(3): 329–335.Google Scholar

Haslemo T, Eikeseth PH, Tanum L, et al. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol. 2006; 62(12): 1049–1053.Google Scholar

Schoretsanitis G, Spina E, Hiemke C, et al. A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. Expert Rev Clin Pharmacol. 2018; 11(6): 625–639.CrossRef Google Scholar

Linnet, K, Wiborg, O. Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Clin Pharmacol Ther. 1996; 60(1): 41–47.Google Scholar

de Leon, J, Sandson, NB, Cozza, KL. A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part II. Psychosomatics. 2008; 49(4): 347–361.Google Scholar

de Leon, J, Wynn, G, Sandson, NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics. 2010; 51(1): 80–88.Google Scholar

Mallikaarjun, S, Kane, JM, Bricmont, P, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res. 2013; 150(1): 281–288.Google Scholar

Marder, SR, Midha, KK, Van Putten, T, et al. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response. Br J Psychiatry. 1991; 158: 658–665.Google Scholar

Jann, MW, Wei, FC, Lin, HN, et al. Haloperidol and reduced haloperidol plasma concentrations after a loading dose regimen with haloperidol decanoate. Prog Neuropsychopharmacol Biol Psychiatry. 1996; 20(1): 73–86.Google Scholar

Schoretsanitis, G, Spina, E, Hiemke, C, et al. A systematic review and combined analysis of therapeutic drug monitoring studies for long- acting paliperidone. Expert Rev Clin Pharmacol. 2018; 11(12): 1237–1253.Google Scholar

Fleischhacker, WW, Eerdekens, M, Karcher, K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry. 2003; 64(10): 1250–1257.Google Scholar

Ivaturi, V, Gopalakrishnan, M, Gobburu, JVS, et al. Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone. Br J Clin Pharmacol. 2017; 83(7): 1476–1498.Google Scholar

Ereshefsky, L, Mascarenas, CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry. 2003; 64(Suppl 16): 1618–1623.Google Scholar PubMed

Samara, MT, Leucht, C, Leeflang, MM, et al. Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry. 2015; 172(7): 617–629.Google Scholar

Midha, KK, Hubbard, JW, Marder, SR, et al. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J Psychiatry Neurosci. 1994; 19(4): 254–264.Google Scholar

Nyberg, S, Dencker, SJ, Malm, U, et al. D(2)- and 5-HT(2) receptor occupancy in high-dose neuroleptic-treated patients. Int J Neuropsychopharmacol. 1998; 1(2):95–101.Google Scholar